Condition: Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8 · Sponsor: Emory University
This early phase 1 trial will investigate the combination of low-dose interleukin-2 (IL-2) and pembrolizumab in patients with previously untreated stage IV non-small cell lung cancer (NSCLC). Preclinical data demonstrate reinvigoration of exhausted T cells into an effector-like phenotype with improved anti-tumor activity in response to this combination. This study will evaluate T cell function as well as clinical outcomes associated with this combination therapy.
This description comes directly from the study's public registry record.
Suresh S. Ramalingam, MD, FACP, FASCO · 404-778-5378 · ssramal@emory.edu
Ralph Millett, MD · rmillet@emory.edu
Always discuss trial participation with your own doctor first.
| Emory University/Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05493566